Vanguard Group Inc. Buys 576,625 Shares of Annexon, Inc. (NASDAQ:ANNX)

Vanguard Group Inc. lifted its stake in Annexon, Inc. (NASDAQ:ANNX) by 11.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,546,918 shares of the company’s stock after purchasing an additional 576,625 shares during the period. Vanguard Group Inc. owned about 5.20% of Annexon worth $28,456,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. State Street Corp grew its stake in Annexon by 116.6% in the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after acquiring an additional 2,068,294 shares in the last quarter. Candriam S.C.A. boosted its holdings in shares of Annexon by 15.6% in the fourth quarter. Candriam S.C.A. now owns 2,534,230 shares of the company’s stock valued at $13,001,000 after purchasing an additional 341,431 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Annexon by 18.3% in the third quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock valued at $12,693,000 after purchasing an additional 331,269 shares during the period. JPMorgan Chase & Co. grew its stake in Annexon by 16.0% in the third quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock worth $10,101,000 after purchasing an additional 235,810 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its holdings in Annexon by 56.2% during the 4th quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company’s stock worth $5,282,000 after purchasing an additional 370,426 shares during the period.

Annexon Price Performance

ANNX stock opened at $1.53 on Tuesday. Annexon, Inc. has a 1 year low of $1.29 and a 1 year high of $7.85. The firm has a market capitalization of $167.86 million, a PE ratio of -1.46 and a beta of 1.24. The business has a 50 day simple moving average of $2.43 and a 200-day simple moving average of $4.52.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). On average, equities research analysts expect that Annexon, Inc. will post -0.96 EPS for the current year.

Analyst Upgrades and Downgrades

ANNX has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Tuesday, March 4th.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.